These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30909009)

  • 21. Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients.
    Arce JC; La Marca A; Mirner Klein B; Nyboe Andersen A; Fleming R
    Fertil Steril; 2013 May; 99(6):1644-53. PubMed ID: 23394782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of antral follicle count and serum anti-Müllerian hormone: Which is better for live birth prediction in patients aged over 40 with their first IVF treatment?
    Lee Y; Kim TH; Park JK; Eum JH; Lee HJ; Kim J; Lyu SW; Kim YS; Lee WS; Yoon TK
    Eur J Obstet Gynecol Reprod Biol; 2018 Feb; 221():151-155. PubMed ID: 29306180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.
    Nardo LG; Gelbaya TA; Wilkinson H; Roberts SA; Yates A; Pemberton P; Laing I
    Fertil Steril; 2009 Nov; 92(5):1586-93. PubMed ID: 18930213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Müllerian hormone serum values and ovarian reserve: can it predict a decrease in fertility after ovarian stimulation by ART cycles?
    Patrelli TS; Gizzo S; Sianesi N; Levati L; Pezzuto A; Ferrari B; Bacchi Modena A
    PLoS One; 2012; 7(9):e44571. PubMed ID: 22984527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Nomogram for Individualized Gonadotropin Starting Dose in GnRH Antagonist Protocol.
    Li Y; Duan Y; Yuan X; Cai B; Xu Y; Yuan Y
    Front Endocrinol (Lausanne); 2021; 12():688654. PubMed ID: 34594300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicenter evaluation of the Access AMH antimüllerian hormone assay for the prediction of antral follicle count and poor ovarian response to controlled ovarian stimulation.
    Baker VL; Gracia C; Glassner MJ; Schnell VL; Doody K; Coddington CC; Shin SS; Marshall LA; Alper MM; Morales AJ; Pavone ME; Behera MA; Zbella EA; Shapiro BS; Straseski JA; Broyles DL
    Fertil Steril; 2018 Aug; 110(3):506-513.e3. PubMed ID: 29960708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of gene polymorphisms and AMH level in prediction of poor ovarian response in Egyptian women undergoing IVF procedure.
    Motawi TMK; Rizk SM; Maurice NW; Maged AM; Raslan AN; Sawaf AH
    J Assist Reprod Genet; 2017 Dec; 34(12):1659-1666. PubMed ID: 28825151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of Letrozole (LE) in controlled ovarian stimulation (COS) in patients at high risk to develop ovarian hyper stimulation syndrome (OHSS). A prospective randomized controlled pilot study.
    Tshzmachyan R; Hambartsoumian E
    J Gynecol Obstet Hum Reprod; 2020 Feb; 49(2):101643. PubMed ID: 31563697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-Müllerian hormone dynamics during GNRH-antagonist short protocol for IVF/ICSI in women with varying ovarian reserve levels.
    Melado Vidales L; Fernández-Nistal A; Martínez Fernández V; Verdú Merino V; Bruna Catalán I; Bajo Arenas JM
    Minerva Ginecol; 2017 Apr; 69(2):128-134. PubMed ID: 27310675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos.
    Majumder K; Gelbaya TA; Laing I; Nardo LG
    Eur J Obstet Gynecol Reprod Biol; 2010 Jun; 150(2):166-70. PubMed ID: 20223579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is assessment of anti-Müllerian hormone and/or antral follicle count useful in the prediction of ovarian response in expected normal responders treated with a fixed dose of recombinant FSH and GnRH antagonists? A prospective observational study.
    Ganidou MA; Kolibianakis EM; Venetis CA; Gerou S; Makedos GA; Klearchou N; Tarlatzis BC
    Gynecol Endocrinol; 2014 Nov; 30(11):817-21. PubMed ID: 24989633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ovarian response to controlled ovarian hyperstimulation: what does serum FSH say?
    Oudshoorn SC; van Tilborg TC; Hamdine O; Torrance HL; Eijkemans MJC; Lentjes EGWM; Lambalk CB; Broekmans FJM
    Hum Reprod; 2017 Aug; 32(8):1701-1709. PubMed ID: 28854580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice.
    La Marca A; Sunkara SK
    Hum Reprod Update; 2014; 20(1):124-40. PubMed ID: 24077980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection.
    Arce JC; Andersen AN; Fernández-Sánchez M; Visnova H; Bosch E; García-Velasco JA; Barri P; de Sutter P; Klein BM; Fauser BC
    Fertil Steril; 2014 Dec; 102(6):1633-40.e5. PubMed ID: 25256937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
    Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
    Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical value of serum anti-mullerian hormone and inhibin B in prediction of ovarian response in patients with polycystic ovary syndrome.
    Zhang F; Liu XL; Rong N; Huang XW
    J Huazhong Univ Sci Technolog Med Sci; 2017 Feb; 37(1):70-73. PubMed ID: 28224431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients.
    Elgindy EA; El-Haieg DO; El-Sebaey A
    Fertil Steril; 2008 Jun; 89(6):1670-6. PubMed ID: 17658520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The dynamics of serum anti-Mullerian-hormone levels during controlled ovarian hyperstimulation with GnRH-antagonist short protocol in polycystic ovary syndrome and low responders.
    Weintraub A; Margalioth EJ; Chetrit AB; Gal M; Goldberg D; Alerhand S; Eldar-Geva T
    Eur J Obstet Gynecol Reprod Biol; 2014 May; 176():163-7. PubMed ID: 24630573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.